[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612797":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":33,"centralContacts":38,"locations":47,"responsibleParty":63,"collaborators":65,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":22,"maxAge":22,"enrollmentInfo":89,"targetDuration":22,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":22,"overallStatus":99,"whyStopped":22,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"The Task Force for Global Health","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Implementation Cohort","EXPERIMENTAL","Implementation Cohort (Single Arm)\n\nInterventions:\n\n1. Drug: Tenofovir Alafenamide (TAF) HBsAg-positive individuals meeting WHO 2024 treatment eligibility criteria will receive daily oral TAF. Tenofovir disoproxil fumarate (TDF) may be used if TAF is unavailable.\n2. Behavioral: Community-Based Support Interventions to improve linkage to care, retention, and treatment adherence4646. This includes telephone calls, home visits by community health volunteers, and phone\u002FSMS reminders for appointments.\n3. Diagnostic Test: Simplified WHO 2024 Criteria HBsAg-positive individuals will be evaluated for treatment eligibility using simplified 2024 WHO guidelines, including APRI score, as an alternative to HBV DNA testing.",[13,14,15],"Drug: Tenofovir Alafenamide (TAF)","Behavioral: Community-Based Support","Diagnostic Test: Simplified WHO 2024 Criteria",[17,23,28],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Tenofovir Alafenamide (TAF)","HBsAg-positive individuals meeting WHO 2024 treatment eligibility criteria will receive daily oral TAF. Tenofovir disoproxil fumarate (TDF) may be used if TAF is unavailable.",[9],null,{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":22},"BEHAVIORAL","Community-Based Support","Interventions to improve linkage to care, retention, and treatment adherence. This includes telephone calls, home visits by community health volunteers, and phone\u002FSMS reminders for appointments.",[9],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":22},"DIAGNOSTIC_TEST","Simplified WHO 2024 Criteria","HBsAg-positive individuals will be evaluated for treatment eligibility using simplified 2024 WHO guidelines, including APRI score, as an alternative to HBV DNA testing.",[9],[34],{"name":35,"affiliation":36,"role":37},"Professor Tawasek Tawandee","Mahidol University","PRINCIPAL_INVESTIGATOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":22,"email":43},"Dr. Gibril Ndow","CONTACT","+1 404 907 9954","gndow@taskforce.org",{"name":45,"role":41,"phone":22,"phoneExt":22,"email":46},"Dr. Wisit Apisitwitaya","wisitapisit1@gmail.com",[48],{"facility":49,"status":22,"city":50,"state":51,"zip":22,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Phichit Provincial Hospital, Phichit \u002F 12 District Hospitals in Phichit Province","Phichit","Changwat Phichit","Thailand","TH",{"type":55,"coordinates":56},"Point",[57,58],100.34879,16.44184,{"lat":58,"lon":57},[61],{"name":45,"role":41,"phone":62,"phoneExt":22,"email":46},"0864456330",{"type":64,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR",[66,69,71,74,76,78],{"name":67,"class":68},"Phichit Provincial Public Health Office, Ministry of Public Health, Thailand (Host institution)","UNKNOWN",{"name":70,"class":68},"Division of Gastroenterology, Department of Medicine Siriraj Hospital, Mahidol University",{"name":72,"class":73},"Ministry of Health, Thailand","OTHER_GOV",{"name":75,"class":68},"Phichit Provincial Hospital",{"name":77,"class":68},"Liver Foundation Thailand",{"name":79,"class":68},"Thai Association for the Study of the Liver","100612797","phase-4-strengthening-hepatitis-b-screening-linkage-to-care-and-long-term-monitoring-in-phichit-province-thailand-a-birth-bohort-approach-100612797",false,"NCT07258251","Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach","HBV-PHICHIT","Inclusion Criteria:\n\n* Adults born before January 1, 1992\n* Residing in Phichit Province\n* Individuals who test positive for HBsAg will be invited to participate in the follow-up cohort\n* HBsAg positive patients who are already under care will also be invited to participate\n\nExclusion Criteria:\n\n* Subjects who withdraw consent",true,"ALL",{"count":90,"type":91},6000,"ESTIMATED","INTERVENTIONAL",[94],"PHASE4","This study in Phichit province, Thailand, aims to find and support adults born before 1992 who are at high risk for hepatitis B infection. Many people in this group were born before the universal hepatitis B vaccine was available and may not know they are infected. The study will invite nearly 240,000 eligible adults for free hepatitis B screening. Those who test positive will be linked to care at one of 12 district hospitals. Doctors will use simplified 2024 World Health Organization (WHO) guidelines to decide who needs treatment. Eligible individuals will receive a safe, effective daily medicine (tenofovir alafenamide). The study will use community health volunteers and phone reminders to help patients stay in care and take their medication regularly. Over three years, the study will track improvements in liver health and virus levels, aiming to prevent liver cirrhosis and cancer.",[97,98],"Chronic Hepatitis B","Hepatitis B Virus Infection","NOT_YET_RECRUITING","2025-11-20",{"date":102,"type":103},"2025-12-02","ACTUAL",{"date":105,"type":91},"2026-01-01",{"date":107,"type":91},"2028-12-31",{"name":5,"class":6},1]